The Washington Post @washingtonpost
Advice: A study showed that lecanemab slowed cognitive decline in patients at an early stage, but it probably won’t benefit patients with non-Alzheimer’s dementia, or those in the later stages of the disease https://t.co/8unt0VpaDl — PolitiTweet.org